Generic User Fees: FDA Wants To Reduce The Number Of Amendments Per Application
This article was originally published in The Pink Sheet Daily
Agency proposes a priority system for ANDA amendments to cut down on "development on the clock"; draft goals letter to be prepared.
You may also be interested in...
Industry and FDA appear largely in agreement on goals for the generic drug user fee program after it gets off the ground, but are stuck on how to determine agency performance in its early years.
FDA remains firm in its push for application completeness in PDUFA V, despite its willingness to add two new review cycle meetings with sponsors.